Are you routinely recommending adjuvant ribociclib now for node-negative HR+/HER2- breast cancer given data from the NATALEE trial?

Yes, I offer eligible node-negative patients, as defined by the NATALEE trial criteria, with anatomic stage II or III hormone receptor-positive breast cancer node-negative patients who are at high risk of recurrence, as defined by and would have met criteria for the NATALEE trial.

The NATALEE trial d...

If patients are meeting the criteria for NATALEE (T2 N0 Grade III, Ki67 >= 20% or high GEP risk defined as RS > 25 or MPI < 0), then I offer them adjuvant CDK4/6i per label. ESMO 2025 5-year analysis demonstrated:

• Overall iDFS HR: 0.716 (95% CI 0.618–0.829)
• 5-year iDFS 85.5% vs 81.0% (absolute +4.5%...

Adjuvant ribociclib has demonstrated a significant benefit in node-negative (N0) patients with HR+/HER2− early breast cancer in the NATALEE trial, expanding its role beyond traditional high-risk, node-positive populations.

NATALEE Trial: Ribociclib in Node-Negative (N0) Patients

Eligibility for N0 Pat...